Switch theme
Sign up to access all valuation multiples
Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market.
2000
n/a
Last FY Revenue $1.7M
Last FY EBITDA -$6.5M
$160M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Genomictree achieved revenue of $1.7M and an EBITDA of -$6.5M.
Genomictree expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genomictree valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.7M | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | -31% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -377% | XXX | XXX | XXX |
| EBIT | XXX | -$11.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -648% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.4M | XXX | XXX | XXX |
| Net Margin | XXX | -434% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genomictree's stock price is KRW 13030 (or $9).
Genomictree has current market cap of KRW 313B (or $227M), and EV of KRW 221B (or $160M).
See Genomictree trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $160M | $227M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genomictree has market cap of $227M and EV of $160M.
Genomictree's trades at 93.4x EV/Revenue multiple, and -24.8x EV/EBITDA.
Equity research analysts estimate Genomictree's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genomictree's P/E ratio is not available.
See valuation multiples for Genomictree and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $227M | XXX | $227M | XXX | XXX | XXX |
| EV (current) | $160M | XXX | $160M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 93.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -24.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -14.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -30.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenomictree's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Genomictree's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genomictree's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genomictree and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -377% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 209% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 617% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomictree acquired XXX companies to date.
Last acquisition by Genomictree was XXXXXXXX, XXXXX XXXXX XXXXXX . Genomictree acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genomictree founded? | Genomictree was founded in 2000. |
| Where is Genomictree headquartered? | Genomictree is headquartered in South Korea. |
| Is Genomictree publicy listed? | Yes, Genomictree is a public company listed on KRX. |
| What is the stock symbol of Genomictree? | Genomictree trades under 228760 ticker. |
| When did Genomictree go public? | Genomictree went public in 2016. |
| Who are competitors of Genomictree? | Similar companies to Genomictree include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Genomictree? | Genomictree's current market cap is $227M |
| Is Genomictree profitable? | Yes, Genomictree is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
